Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics
Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling
Clinical Scorecard: Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics
At a Glance
| Category | Detail |
|---|
| Condition | Myeloproliferative Neoplasms (MPNs) |
| Key Mechanisms | Next-generation sequencing (NGS) and high-sensitivity PCR for detecting mutations in driver genes. |
| Target Population | Patients with suspected myeloproliferative neoplasms. |
| Care Setting | Clinical laboratories and oncology practices. |
Key Highlights
- NGS reveals driver, co-mutation, and resistance profiles that inform prognosis and therapy.
- 90% of MPNs carry mutations in JAK2, CALR, or MPL.
- NCCN guidelines recommend NGS for diagnostic and prognostic evaluation of MPNs.
- NGS can uncover co-mutations with significant prognostic implications.
- Sequential PCR testing may miss important co-mutations.
Guideline-Based Recommendations
Diagnosis
- Use NGS panels for comprehensive genomic assessment in MPN diagnostics.
Management
- Incorporate findings from NGS into treatment planning for precision-based management.
Monitoring & Follow-up
- Monitor for co-mutations that may affect prognosis and treatment options.
Risks
- Relying solely on PCR may lead to missed diagnoses and inappropriate treatment strategies.
Patient & Prescribing Data
Patients with MPNs, particularly those with atypical or compound mutations.
IDH inhibitors may be considered for patients with IDH2 mutations.
Clinical Best Practices
- Utilize a diagnostic algorithm integrating both NGS and PCR.
- Consider NGS for patients with low variant allele frequency in driver genes.
- Assess for co-mutations that may influence prognosis and treatment.
References
